BLCM Bellicum Pharmaceuticals Inc

Price (delayed)

$1.53

Market cap

$13.18M

P/E Ratio

21.86

Dividend/share

N/A

EPS

$0.07

Enterprise value

-$21.49M

Bellicum is a clinical stage biopharmaceutical company striving to deliver cures through controllable cell therapies. The company's next-generation product candidates are differentiated by powerful cell signaling technologies designed to produce ...

Highlights
The company's debt has shrunk by 100% YoY
The quick ratio has increased by 48% QoQ
The equity has soared by 199% YoY but it has decreased by 19% from the previous quarter
BLCM's EPS has shrunk by 97% YoY
BLCM's net income is down by 30% since the previous quarter

Key stats

What are the main financial stats of BLCM
Market
Shares outstanding
8.61M
Market cap
$13.18M
Enterprise value
-$21.49M
Valuations
Price to earnings (P/E)
21.86
Price to book (P/B)
0.94
Price to sales (P/S)
8.58
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-3.91
Earnings
Revenue
$5.5M
EBIT
-$7.8M
EBITDA
-$7.76M
Free cash flow
-$20.01M
Per share
EPS
$0.07
Free cash flow per share
-$0.65
Book value per share
$1.63
Revenue per share
$0.18
TBVPS
$1.19
Balance sheet
Total assets
$36.6M
Total liabilities
$4.53M
Debt
$0
Equity
$14.04M
Working capital
$32.06M
Liquidity
Debt to equity
0
Current ratio
8.07
Quick ratio
7.7
Net debt/EBITDA
4.47
Margins
EBITDA margin
-141%
Gross margin
100%
Net margin
-141.8%
Operating margin
-374.6%
Efficiency
Return on assets
-21.8%
Return on equity
-75.7%
Return on invested capital
N/A
Return on capital employed
-24.3%
Return on sales
-141.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BLCM stock price

How has the Bellicum Pharmaceuticals stock price performed over time
Intraday
5.52%
1 week
11.79%
1 month
28.14%
1 year
-45.55%
YTD
2.68%
QTD
28.57%

Financial performance

How have Bellicum Pharmaceuticals's revenue and profit performed over time
Revenue
$5.5M
Gross profit
$5.5M
Operating income
-$20.6M
Net income
-$7.8M
Gross margin
100%
Net margin
-141.8%
The company's net margin has shrunk by 138% YoY and by 46% QoQ
BLCM's operating margin has surged by 89% year-on-year but it is down by 6% since the previous quarter
Bellicum Pharmaceuticals's operating income has soared by 50% YoY and by 6% from the previous quarter
BLCM's net income is down by 30% since the previous quarter

Growth

What is Bellicum Pharmaceuticals's growth rate over time

Valuation

What is Bellicum Pharmaceuticals stock price valuation
P/E
21.86
P/B
0.94
P/S
8.58
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-3.91
BLCM's EPS has shrunk by 97% YoY
The equity has soared by 199% YoY but it has decreased by 19% from the previous quarter
BLCM's P/S is 97% below its 5-year quarterly average of 248.1 but 38% above its last 4 quarters average of 6.2
BLCM's revenue is down by 11% QoQ

Efficiency

How efficient is Bellicum Pharmaceuticals business performance
BLCM's ROS has shrunk by 132% YoY and by 46% QoQ
The ROE has soared by 55% from the previous quarter
Bellicum Pharmaceuticals's return on assets has decreased by 17% QoQ

Dividends

What is BLCM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BLCM.

Financial health

How did Bellicum Pharmaceuticals financials performed over time
BLCM's total liabilities has dropped by 78% year-on-year and by 43% since the previous quarter
The total assets has surged by 53% year-on-year but it has declined by 16% since the previous quarter
The company's debt is 100% lower than its equity
The equity has soared by 199% YoY but it has decreased by 19% from the previous quarter
The company's debt has shrunk by 100% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.